Sanofi's Plavix gets priority review in Japan

PARIS, July 4 (Reuters) - French drugmaker Sanofi-Aventis (SASY.PA: Quote, Profile, Research, Stock Buzz) said on Wednesday its bloodclot treatment product Plavix had received a priority review in Japan for a supplemental new drug application to treat acute coronary syndrome. Sanofi shares fell sharply last month after a U.S. health panel advised against approving its weight loss pill Acomplia over concerns it may be linked to suicide.

Plavix is marketed in 85 countries by Sanofi and U.S. group Bristol Myers Squibb Co (BMY.N: Quote, Profile, Research, Stock Buzz), who many see as a possible merger partner for Sanofi.

((Reporting by Sudip Kar-Gupta; Reuters Messaging: sudip.kargupta.reuters.com@reuters.net; +33 1 49 49 54 52)) Keywords: SANOFI PLAVIX/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWLA1098